STOCK TITAN

Neurocrine officer plans sale of 2,154 shares

NEUROCRINE BIOSCIENCES, INC.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES, INC. (NBIX) received a Rule 144 notice that officer Eric Benevich plans to sell up to 2,154 shares of common stock. The shares are expected to be sold on or about September 9, 2026 on NASDAQ through Morgan Stanley Smith Barney LLC after a cash exercise of stock options.

Positive

  • None.

Negative

  • None.
Shares to be sold under Rule 144 2,154 shares Planned sale of Neurocrine Biosciences, Inc. common stock by an officer
Expected sale date September 9, 2026 Planned disposition date for the 2,154 shares
Form type Rule 144 notice of proposed sale Notice filed for planned sale of restricted/controlled securities
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Exercise of Stock Options financial
"Common | 09/09/2026 | Exercise of Stock Options | Issuer"
Executive Financial Services financial
"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

What does the Rule 144 filing disclose for NBIX?

It discloses that officer Eric Benevich intends to sell up to 2,154 shares of Neurocrine Biosciences, Inc. common stock under Rule 144, with sales expected around September 9, 2026 after a cash exercise of stock options.

How many NBIX shares are planned for sale in this Rule 144 notice?

The notice reports a planned sale of up to 2,154 shares of Neurocrine Biosciences, Inc. common stock. This figure represents the amount covered by the Rule 144 filing for proposed disposition.

When are the NBIX shares expected to be sold under this Rule 144 filing?

The filing lists an expected sale date of September 9, 2026 for the 2,154 shares of Neurocrine Biosciences, Inc. common stock to be sold under Rule 144.

What is the source of the NBIX shares being sold in this filing?

The shares are to be issued through an exercise of stock options on September 9, 2026, with the exercise paid in cash, and then sold under Rule 144.

Which broker is named for the NBIX Rule 144 sale?

The planned sale of 2,154 shares of Neurocrine Biosciences, Inc. common stock is to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services, with trading on NASDAQ as stated in the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading